Enliven Therapeutics, Inc. (ELVN)
(Delayed Data from NSDQ)
$27.31 USD
+2.29 (9.15%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $27.24 -0.07 (-0.26%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Enliven Therapeutics, Inc. (ELVN) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$34.00 | $38.00 | $32.00 | 35.89% |
Price Target
Based on short-term price targets offered by four analysts, the average price target for Enliven Therapeutics, Inc. comes to $34.00. The forecasts range from a low of $32.00 to a high of $38.00. The average price target represents an increase of 35.89% from the last closing price of $25.02.
Analyst Price Targets (4 )
Broker Rating
Enliven Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by five brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on five recommendations.
Of the five recommendations deriving the current ABR, five are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 4 | 4 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/11/2024 | Robert W. Baird & Co. | Colleen M Kusy | Not Available | Strong Buy |
5/15/2024 | LifeSci Capital | Sam Slutsky | Strong Buy | Strong Buy |
4/9/2024 | Mizuho SecuritiesUSA | Salim Syed | Not Available | Strong Buy |
4/1/2024 | Cowen & Co. | Philip M Nadeau | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 5 |
Average Target Price | $34.00 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 97 of 252 |
Current Quarter EPS Est: | -0.58 |